Ironwood Pharmaceuticals, Inc. (IRWD)
NASDAQ: IRWD · Real-Time Price · USD
4.450
+0.570 (14.69%)
At close: Dec 20, 2024, 4:00 PM
4.610
+0.160 (3.60%)
After-hours: Dec 20, 2024, 6:11 PM EST
Ironwood Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for IRWD stock have an average target of 12, with a low estimate of 5.00 and a high estimate of 21. The average target predicts an increase of 169.66% from the current stock price of 4.45.
Analyst Consensus: Buy
* Price targets were last updated on Sep 9, 2024.
Analyst Ratings
The average analyst rating for IRWD stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Hold Initiates $5 | Hold | Initiates | $5 | +12.36% | Sep 9, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $14 → $12 | Buy | Maintains | $14 → $12 | +169.66% | Aug 9, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $14 → $10 | Strong Buy | Maintains | $14 → $10 | +124.72% | Aug 9, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +214.61% | May 10, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $20 → $14 | Buy | Maintains | $20 → $14 | +214.61% | Mar 1, 2024 |
Financial Forecast
Revenue This Year
360.44M
from 442.74M
Decreased by -18.59%
Revenue Next Year
355.39M
from 360.44M
Decreased by -1.40%
EPS This Year
0.12
from -6.45
EPS Next Year
0.31
from 0.12
Increased by 167.83%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 375.5M | 394.6M | 560.9M | |||
| Avg | 360.4M | 355.4M | 424.5M | |||
| Low | 342.7M | 296.0M | 348.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -15.2% | 9.5% | 57.8% | |||
| Avg | -18.6% | -1.4% | 19.4% | |||
| Low | -22.6% | -17.9% | -2.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.27 | 0.60 | 1.18 | |||
| Avg | 0.12 | 0.31 | 0.77 | |||
| Low | 0.05 | 0.13 | 0.46 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 410.2% | 274.3% | |||
| Avg | - | 167.8% | 145.7% | |||
| Low | - | 8.6% | 46.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.